Thor Medical (TRMED.OL)

Executive Summary

Thor Medical ASA is a Norwegian radiopharmaceutical company developing a proprietary, environmentally friendly process to extract alpha-emitting isotopes, including Radium-224 and Lead-212, from natural thorium-232. These isotopes are used in targeted alpha therapy (TAT) for cancer, a rapidly growing field due to their potent and precise tumor-killing capabilities. The company operates a pilot facility and is scaling toward commercial production, positioning itself as a potential world-leading supplier in the high-growth radiopharmaceutical market. With increasing demand for TAT isotopes and limited supply, Thor Medical's technology offers a scalable, cost-effective solution. The company is privately held and listed on the Oslo Stock Exchange (ticker: TRMED.OL), with a strong intellectual property portfolio and a clear strategy to meet clinical and commercial needs. As the radiopharmaceutical sector expands, Thor Medical is well-placed to capture value by providing critical raw materials for next-generation cancer therapies.

Upcoming Catalysts (preview)

• Q4 2026Completion of Commercial-Scale Production Facility80% success
• Q1 2027First Binding Supply Agreement with a Pharmaceutical Partner65% success
• Q2 2027Regulatory Designation (e.g., FDA Orphan Drug) for Lead-212 Based Therapy50% success